Choosing a Translation Vendor for your Market Research Surveys

Technology has made it easier now than ever to reach and assess the global pharma audience using online surveys to obtain physician prescribing behavior. But undertaking this relies heavily on response rates. How can you boost these rates globally?  You need a specialized translation partner —one who understands the goals and strategies you are using,…

Improving your global brand management

In our global world, it’s amazing to think that, not too long ago, branching out your company’s reach was pretty much unheard-of.  Still, even though things like faster travel and mass communications have made international business feasible, that doesn’t mean it’s easy.  Some brands try to go beyond borders and fail.  Others manage, but only…

Not sure this is okay, Cupid.…

In late July, the internet was shaken by a shocking revelation (even by internet standards): Christian Rudder, co-founder and president of OKCupid, announced that the dating site, one of the most popular on the web, had been collecting data to learn more about its users. Not too much to be surprised about there; unless you’re…

Survey says: You can’t always trust statistics

Nine out of ten journalists say that statistics are an important part of their research and reporting.  Okay, I made that up, but it seems like the truth.  Statistics are little bits of information that easily illustrate the scope of something. They also feel reliable. Maybe that’s because you can check who conducted a study…

Blurred Lines: Do Linear Ads Trigger Change?

The July 17th issue of the Journal of the American Medical Association reported on some results from the Global Adult Tobacco Survey which examined if antismoking messages on television, radio, billboards, newspapers or magazines are influencing smoker’s plans to quit.  The good news is they are, the more interesting question is are they sending the…

It’s in the Details (or is it?)

At the Pfizer annual shareholder meeting at the end of April in New Jersey, Pfizer’s CEO Ian Read agreed with comments that the Obama administration’s academic detailing program operates from a conflict of interest. Pharmaceutical interests have come out of the wood work crying “foul” and want the project scrapped.  The conflict of interest arises…